Blood transfusion is a routine but complex medical intervention whose value depends on a patient’s condition, the product administered, its dose, the indication and the surrounding clinical context. Existing large databases connect transfusion exposures with health records and mortality data, but often lack the precise reasons for individual decisions and do not systematically capture how patients function months or years afterward. This limits efforts to assess guideline adherence, compare practice across institutions and determine whether variations in treatment are associated with meaningful differences in recovery. The new registry was designed to close that gap by collecting standardized clinical information at the point of care and using automated questionnaires to build longitudinal patient profiles over a planned period of up to 30 years.

The framework is called the Registry Study for Research of Blood Donor and Recipient Long-Term Outcomes and is built on OSSE, an open-source registry platform. It uses three electronic case-report forms covering basic demographics, transfusions and related blood therapies, and patient-reported outcome measures. Diagnoses and procedures are recorded as SNOMED CT concepts, allowing clinical events to be represented in a standardized, reusable format. Medical staff can enter records through a graphical interface from any internet-connected device, while participating hospitals retain equal roles in the project’s scientific governance. A centralized structure makes network-scale analysis possible in principle, although that capability was not evaluated in this single-center pilot.

Privacy is built into the architecture rather than added after collection. The OSSE system physically separates identifying information, stored in a distinct data environment, from medical information, while double pseudonymization via the Mainzelliste supports secure data exchange. Participants consent to the registry and may withdraw at any time. The approach follows data-minimization principles by limiting identifying data to fields such as name, year of birth, city of residence and contact email. The follow-up system sends a single-use personalized link by email, allowing patients to answer from any device without creating a conventional password or complex authorization process. The pilot operated in German and English, and the platform has since expanded to 16 European and Asian languages.

Clinical forms capture weight, height, documented sex, primary and secondary diagnoses, physical capacity, frailty, blood-group antigens, laboratory measurements and detailed information about each treatment. The registry records the product, date, dose, specific indication, relevant laboratory values before and after administration, and details of the clinical intervention. Physical capacity is graded in five activity-anchored metabolic-equivalent categories based on the Duke Activity Status Index, while frailty is assessed with the Clinical Frailty Scale. The electronic form also links hemorrhage risk to the anesthesiologic assessment and records discharge information. In-hospital mortality was omitted from the original pilot form but has since been added to the current iteration.

Long-term questionnaires ask patients about new diagnoses, anemia and its treatment, subsequent blood-product exposure, related adverse events, pregnancies and births, and changes in physical capacity and frailty. Every question permits an “I do not know” or “I do not want to answer” option, and the interface uses layered filters to make each questionnaire take approximately five minutes. Follow-up is anchored to the first administration, with a first questionnaire after three months and annual assessments thereafter. By the analysis cutoff of 13 August 2026, 43 of 345 eligible patients had responded at three months and 47 of 310 at one year. Paired baseline and follow-up scores were available for small subsets: 20 patients for frailty at three months, 21 for physical capacity at three months, and 20 and 14, respectively, at one year.

The enrolled population was concentrated in cardiac surgery, which limits the pilot’s generalizability. Most participants were scheduled for surgery, and 89.9% of those with a documented risk category were classified as having high expected hemorrhage risk, defined as at least 500 ml. Among 343 patients with documented sex, 245 were male and 98 female. Red-cell concentrates were the most frequently administered therapy, with 363 administrations, followed by 280 albumin administrations and 271 prothrombin complex concentrate administrations; no oral iron administrations were recorded. The registry recorded 319 distinct SNOMED CT concepts, and common entries included coronary arteriosclerosis, hypertensive disorder, aortic valve replacement and other cardiac procedures. These results show the breadth of information the platform can capture, but they describe one center’s case mix rather than transfusion practice in general.

Detailed red-cell data illustrate how the system connects decisions, biology and treatment effects. Among 363 administrations, 360 had a documented indication. The most common was a hemoglobin concentration of 7–8 g/dl accompanied by signs of anemic hypoxia or cardiovascular risk factors, recorded in 250 cases, or 69.4% of administrations with a documented indication. Pre-transfusion hemoglobin averaged 7.72 ± 0.89 g/dl in males and 7.64 ± 0.88 g/dl in females. Among 329 paired laboratory measurements, hemoglobin increased from 7.69 ± 0.89 g/dl before transfusion to 8.80 ± 0.99 g/dl afterward, a mean rise of 1.11 ± 0.99 g/dl. This before-and-after measurement documents the immediate physiological response, but the study did not perform a patient-level assessment of whether each transfusion complied with guidelines.

Sex-disaggregated analyses identified differences that the registry is intended to help investigate. A higher proportion of female patients received red cells, whereas male patients more frequently received platelet concentrate, prothrombin complex concentrate and fibrinogen. Some differences coincided with the surgical procedures recorded in the cohort: aortic valve replacement and bypass grafting were more frequent among men, while mitral valve procedures were more frequent among women. Once dosage was adjusted for body size, the investigators found no clear sex difference. The patterns therefore cannot be interpreted as evidence of inappropriate treatment, and the authors noted that comorbidity, surgical type and biometric factors require examination in larger multicenter cohorts.

Several capabilities remain aspirational. The framework is designed to support risk-adjusted institutional benchmarking, patient-level profiles, network analyses, donor outcomes and real-time dashboards, but the pilot evaluated descriptive institutional analyses only. Structured exchange through HL7 FHIR is also planned and not yet implemented, while crossmatch-to-transfusion data needed to quantify waste from unused blood-product reservations are not recorded. The low follow-up rates create possible non-response bias; although respondents resembled the wider cohort in age and sex, other differences cannot be excluded. Consequently, the paired functional assessments demonstrate that a suitable data structure can be created, not that representative recovery trajectories have already been measured. The registry continued expanding after the pilot, reaching 891 patients and 2,882 documented administrations by 11 September 2026, with a second German center being established and participation open to additional institutions.

Subject of Research: Feasibility of a prospective registry linking transfusion practice with long-term patient-reported outcomes.

Article Title: A Web-Based Registry Framework Linking Transfusion Practice to Long-Term Patient Outcomes: Design and Single-Center Feasibility Study

Article References: Nürenberg-Goloub, E., Friedrichson, B., Nordine, M., Storf, H., Zacharowski, K., & Kloka, J. A. (2026). A Web-Based Registry Framework Linking Transfusion Practice to Long-Term Patient Outcomes: Design and Single-Center Feasibility Study. Journal of Medical Systems, 50(1), Article 153. https://doi.org/10.1007/s10916-026-02474-2

Image Credits: AI Generated

DOI: 10.1007/s10916-026-02474-2

Keywords: blood transfusion, patient registry, long-term outcomes, patient-reported measures, SNOMED CT, health data, privacy by design, digital follow-up, cardiac surgery, blood safety, Web-Based, Registry

Free flap transplantation transfers living tissue, together with its own blood supply, to repair severe soft-tissue defects or reconstruct limb and external-organ functions. Although advances in microsurgical anastomosis, instruments and robotic surgery have improved the quality of vascular connections, postoperative vascular crises remain a major perioperative complication. Such events can compromise flap viability, require emergency salvage surgery, prolong hospitalization and contribute to permanent impairment of limb function. The study was conducted at No. 971 Hospital of the People’s Liberation Army Navy in China using clinical records from January 2012 through August 2023. Among 1,084 records screened, investigators included 568 patients aged 6 years or older who completed free flap surgery. They excluded non-free flap procedures, operations converted to another procedure, patients younger than 6 and patients classified as American Society of Anesthesiologists Physical Status class IV or V.

To separate model development from later validation, the researchers divided the patients chronologically, using December 31, 2020 as the cutoff. Records from 402 earlier patients formed the training cohort, while 166 later patients formed the validation cohort. The training group included 42 vascular crises, or 10.4% of its patients, and the validation group included 21, or 12.7%. The overall median age was 44 years, with an interquartile range of 31–51 years, and the median operative duration was seven hours, with an interquartile range of 5.5–8.5 hours. Most participants were men. Common flap types included anterolateral thigh, forearm and thoracoumbilical flaps. Anterolateral thigh flaps had the greatest absolute number of crises and necroses, but the study did not establish flap type as an independent predictor or demonstrate that the observed counts represented higher within-type risks.

Vascular crisis was diagnosed through bedside assessment of flap color, temperature, capillary refill time, tension and bleeding after pinprick. A pale or gray flap with reduced temperature, prolonged or absent capillary refill and little or no bleeding was considered suspicious for arterial compromise. A dark-red or cyanotic flap with swelling, increased tension and profuse dark-red bleeding suggested venous compromise. Two senior microsurgeons independently assessed and confirmed all cases, resolving discrepancies through discussion or consultation with another senior microsurgeon. Of the 63 crises, 37 patients underwent surgical exploration; arterial crisis was confirmed in 22 and venous crisis in 15. Another 26 patients had findings consistent with mild venous crisis and improved with conservative measures, including removal of sutures to relieve tension, incision and bloodletting for decompression, and volume expansion. Seventeen flaps were lost overall, producing a flap survival rate of 97.0%.

Univariate screening in the training cohort identified 13 variables for inclusion in multivariable modeling. Stepwise multivariable logistic regression then identified four independent statistical associations with vascular crisis. Each 1 g/L increase in serum albumin was associated with an odds ratio of 0.927, with a 95% confidence interval of 0.868–0.991, indicating that higher albumin was associated with lower odds of crisis. Smoking had an odds ratio of 4.713 compared with non-smoking, with a 95% confidence interval of 2.184–10.171. Each 1 g/L increase in hemoglobin had an odds ratio of 0.971, with a 95% confidence interval of 0.952–0.990. Each additional unit of packed red blood cell transfusion had an odds ratio of 1.170, but its 95% confidence interval of 0.993–1.377 included 1 and its P value was 0.060. The authors nevertheless retained transfusion as one of the four variables in the nomogram. These retrospective associations do not show that changing any factor would prevent a crisis.

The nomogram translates the four inputs into points that are summed and converted into a predicted probability. The researchers also created a dynamic online calculator that returns a risk estimate and 95% confidence interval. In the training cohort, the area under the receiver operating characteristic curve was 0.817, with a 95% confidence interval of 0.747–0.887. In the later validation cohort, it was 0.852, with a 95% confidence interval of 0.774–0.929. Calibration analysis showed agreement between predicted and observed risk, with a mean absolute error of 0.019, corresponding to an average prediction error of 1.9%. Decision curve analysis indicated clinical utility across a modeled risk-threshold range of 1% to 51%. A complete-case sensitivity analysis produced results consistent with the primary analysis. The online tool and transparent point system make the model accessible without specialized computing equipment, but its usefulness still depends on accurate inputs and validation in the intended clinical setting.

Several biological pathways could connect the selected variables with flap failure, although the retrospective data cannot determine which mechanisms were responsible. The authors interpreted lower albumin as a marker of poorer perioperative nutritional or physiological condition, noting that low albumin can alter colloid osmotic pressure, promote edema and contribute to impaired microcirculation. Smoking was associated with the largest odds ratio in the model and has a plausible vascular relationship because tobacco constituents can affect endothelial function, vasoconstriction, inflammation and thrombosis. Hemoglobin was included because it determines oxygen-carrying capacity, although the relationship is complex: anemia may reduce oxygen delivery to a flap, while moderate to severe blood loss can trigger redistribution of blood flow away from peripheral tissues. The model measured these relationships statistically rather than testing them experimentally or establishing a causal pathway.

Packed red blood cell transfusion requires particular caution because the model cannot distinguish a direct transfusion effect from confounding by anemia, blood loss or hemodynamic instability. Transfusion may be administered after substantial blood loss or in response to high-risk anemia, so it can also act as an indicator of compromised circulatory status. The authors discussed possible effects of transfused blood, including reduced nitric oxide availability, enhanced endogenous coagulation and inflammatory and endothelial activation. Their mechanistic discussion also relied partly on previous animal research, which cannot establish clinical benefit or harm in patients. The retrospective association between transfusion and vascular crisis should therefore not be interpreted as evidence that transfusion causes the complication, nor does the model establish a safe or unsafe transfusion threshold for free flap surgery.

The model is notable for combining preoperative laboratory measures with smoking and a perioperative transfusion variable in a transparent logistic-regression framework, while its simplicity also defines its limitations. The retrospective, single-center design leaves room for selection, measurement and unmeasured-confounding biases. Seventy patients, or 12.3% of the cohort, had at least one missing value, principally unavailable preoperative liver or kidney test results and missing intraoperative urine-output data. The investigators imputed missing continuous values with means or medians according to distribution and categorical values with modes, then conducted a complete-case sensitivity analysis. The four-variable model did not explicitly include surgical site, flap type, number of anastomosed vessels or other measures of surgical quality. It also included only 63 endpoint events across the full dataset, so some coefficient estimates, particularly for transfusion, carry substantial uncertainty.

Validation was limited to a chronologically later subset from the same hospital rather than an independent external cohort. The validation sample was modest, containing only 21 vascular crises, and the confidence intervals around discrimination were correspondingly broad. Prospective, multicenter studies would be needed to determine whether the nomogram retains its performance across different institutions, flap procedures and patient populations, and whether using it to guide perioperative care improves outcomes. The findings do not show that the model can prevent thrombosis or reduce flap loss. Instead, they provide a calibrated risk estimate for postoperative vascular crisis based on four routinely available factors, offering a potential screening aid for closer observation while leaving real-world clinical value and generalizability for further study.

Subject of Research: Development and internal validation of a four-factor nomogram for predicting vascular crisis after free flap surgery.

Article Title: Construction and validation of a predictive nomogram for vascular crisis risk following free flap surgery

Article References: Qu, Y.-L., Xue, J., Du, X.-Y., Zhang, D.-D., Wang, Y., Zhu, Y.-L., & Wang, J.-F. (2026). Construction and validation of a predictive nomogram for vascular crisis risk following free flap surgery. Frontiers in Medicine, 13, Article 1930369. https://doi.org/10.3389/fmed.2026.1930369

Image Credits: AI Generated

DOI: 10.3389/fmed.2026.1930369

Keywords: free flap surgery, vascular crisis, risk prediction, clinical nomogram, flap thrombosis, serum albumin, smoking, hemoglobin, blood transfusion, internal validation, Construction, validation

The study, published in the Annals of Hematology, drew on the National Inpatient Sample, the largest publicly available all-payer hospital database in the United States. The researchers, led by co-first authors May AlMoshary of Princess Nourah bint Abdulrahman University in Riyadh and Ahmed Elbataa of Al-Azhar University in Cairo, examined seven years of admissions data spanning 2016 through 2022. They identified 191,640 weighted hospitalizations of adults admitted with a principal diagnosis of acute leukemia, using standardized ICD-10-CM diagnostic codes to ensure consistent case identification across hundreds of hospitals nationwide.

Within that enormous cohort, 8,880 hospitalizations, or 4.6 percent, involved venous thromboembolism. That figure may sound modest, but in the context of a disease whose treatment already involves profound disruptions of the blood system, it represents a substantial clinical burden. More troubling is the trajectory: after adjusting for patient and hospital characteristics, the prevalence of venous thromboembolism climbed significantly between 2016 and 2022, a trend the authors describe as statistically robust with a p-value of 0.032. The burden peaked at 5.3 percent in 2021, suggesting that the pressures of the pandemic era, or evolving treatment patterns, may have intensified the thrombotic risk faced by leukemia patients.

Acute leukemia occupies a peculiar and dangerous position in hematology. Unlike solid tumors, which promote clotting through local inflammation and vessel compression, leukemia floods the bone marrow and bloodstream with malignant white blood cells that actively subvert the coagulation system. Patients simultaneously face thrombocytopenia, a dangerous shortage of platelets that predisposes them to catastrophic bleeding, and a hypercoagulable state driven by tumor cell procoagulants, inflammatory cytokines, and chemotherapy itself. The result is a clinical tightrope: the same patient may need transfusions to survive a hemorrhage and anticoagulants to survive a clot, often within the same hospital week.

This competing thrombohemorrhagic dynamic is precisely why the research team chose blood product transfusion as the primary outcome of their analysis. Transfusion requirements, they argue, serve as a clinically meaningful proxy for the overall balance between clotting and bleeding that defines acute leukemia care. What they found was unexpected. After multivariable adjustment, patients with venous thromboembolism actually had lower odds of receiving a blood product transfusion, with an adjusted odds ratio of 0.842. The authors are careful about interpretation, noting that this paradoxical inverse association may reflect unmeasured disease severity rather than a genuine protective effect, and that clinicians may withhold transfusions or anticoagulation in ways that confound simple associations.

The other outcomes were far less ambiguous. Venous thromboembolism was independently associated with a 47.8 percent increase in the odds of dying in the hospital, an adjusted odds ratio of 1.478 with a p-value below 0.001. Patients with clots stayed in the hospital dramatically longer, an average of 8.41 additional days, and generated substantially higher costs, with inflation-adjusted hospital charges exceeding those of clot-free admissions by an average of $127,633. For a disease already among the most expensive to treat in medicine, the economic toll of thrombotic complications alone is staggering.

Methodological rigor is a strength of the analysis. Because the National Inpatient Sample uses a complex survey design with weighting to represent the full national population of hospitalizations, the researchers employed multivariable regression models that accounted for that design, ensuring their estimates reflect national patterns rather than the quirks of any hospital subset. To test the durability of their findings, they ran propensity-score weighted sensitivity analyses using average treatment effect on the treated weights, a technique that statistically balances the clot and no-clot groups on observed characteristics. Every major association, from the mortality signal to the transfusion paradox, remained stable under this scrutiny.

The rising trend in clot prevalence deserves particular attention. Several forces could be driving it. Treatment landscapes for acute leukemia have shifted over the study window, with wider adoption of intensive induction regimens, novel targeted agents, and supportive care advances that keep patients alive longer and thus exposed to thrombotic risk for greater spans of time. Improved imaging, particularly more routine use of computed tomography pulmonary angiography, may also be detecting clots that previously went undiagnosed. And the 2021 peak coincides with the COVID-19 pandemic, a period when viral infection itself became a potent prothrombotic force and hospital systems were strained to their limits.

For clinicians, the message is that venous thromboembolism should be treated as a first-order complication of acute leukemia rather than an afterthought. Prophylaxis decisions in this population are genuinely difficult, because standard anticoagulation carries hemorrhagic risk in patients whose platelet counts can plummet without warning. Yet the mortality association documented here suggests that under-recognition or undertreatment of thrombosis carries its own lethal price. The authors suggest that their nationally representative figures can help calibrate risk-benefit calculations, identifying which hospitalized leukemia patients might merit closer surveillance, earlier imaging, or tailored prophylactic strategies.

The study also carries implications for health systems and researchers. The added length of stay and cost burden quantified here, more than eight extra bed-days and over $127,000 in additional charges per complicated admission, translate into enormous aggregate expenditure when multiplied across the tens of thousands of leukemia admissions each year. Future work, the team notes, should probe the mechanisms behind the transfusion paradox and the drivers of the rising trend, ideally with granular clinical data that the administrative coding of the National Inpatient Sample cannot provide. For now, the analysis stands as one of the clearest national portraits to date of a quiet killer complicating one of medicine’s most aggressive cancers, and a reminder that in acute leukemia, the battle between clotting and bleeding is fought on every hospital ward, every day.

Subject of Research: Venous thromboembolism prevalence and inpatient outcomes in hospitalized adults with acute leukemia in the United States, 2016–2022

Article Title: National trends and inpatient outcomes of venous thromboembolism in hospitalized acute leukemia: a propensity-score weighted analysis, 2016–2022

Article References: AlMoshary, M., Elbataa, A., Mansour, A., Murad, M. R., Alabed, A., ALSubhi, S. A., Alzarea, E. A., Halawani, S. H., Bajuaifer, N. A., Basonbul, A. A., Abdelbary, L., & Bakhsh, E. (2026). National trends and inpatient outcomes of venous thromboembolism in hospitalized acute leukemia: a propensity-score weighted analysis, 2016–2022. Annals of Hematology. https://doi.org/10.1007/s00277-026-07312-6

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07312-6

Keywords: venous thromboembolism, acute leukemia, National Inpatient Sample, in-hospital mortality, blood transfusion, hospital length of stay, propensity-score weighting, hematology, thrombosis, hospitalization costs, ICD-10-CM, retrospective cohort

For most of the twentieth century, transfusion practice was governed by the so-called 10/30 rule, under which clinicians transfused red blood cells whenever hemoglobin fell below 10 grams per deciliter or hematocrit dropped below 30 percent. That convention rested largely on expert judgment rather than controlled evidence. The landscape shifted decisively in 1999 with the Transfusion Requirements in Critical Care (TRICC) trial, in which 838 critically ill adults in Canadian intensive care units were randomized to a restrictive strategy, transfusing at a hemoglobin threshold of 7 grams per deciliter, or a liberal strategy with a threshold of 10. The restrictive arm produced no increase in 30-day mortality, and in younger and less severely ill patients it was actually associated with lower mortality, alongside a substantial reduction in blood product use.

Subsequent landmark trials extended that message across specialties. The FOCUS trial, published in 2011, enrolled more than 2,000 older patients with cardiovascular risk factors after hip fracture surgery and found no differences in death, inability to walk unaided at 60 days, cardiovascular events, or hospital stay between a liberal threshold of 10 grams per deciliter and a restrictive threshold of 8. The TRACS trial in cardiac surgery compared a restrictive hematocrit target of roughly 24 percent with a liberal target of 30 percent and showed non-inferiority for mortality and major complications. The TITRe2 trial, spanning more than 2,000 cardiac surgery patients in the United Kingdom, confirmed fewer transfusions with a restrictive threshold of 7.5 grams per deciliter, although a secondary analysis hinted at a modest mortality increase that was not the primary endpoint, leaving interpretation contested.

Some of the most striking results came from gastroenterology. In a 2013 study, Villanueva and colleagues randomized patients with acute upper gastrointestinal bleeding to restrictive or liberal transfusion, using thresholds of 7 and 9 grams per deciliter respectively. The restrictive approach was associated with significantly lower mortality, less rebleeding, shorter hospital stays, and fewer complications, an effect particularly pronounced in patients with portal hypertension and cirrhosis. The proposed mechanism is physiological: excessive transfusion raises portal venous pressure, which can worsen variceal bleeding and impede hemostasis. More recently, the TRISS trial in septic shock randomized over 1,000 patients to hemoglobin targets of 7 or 9 grams per deciliter and found no significant differences in mortality or ischemic events, while the restrictive arm cut red cell use by roughly half.

The physiological rationale for these findings lies in the body’s remarkable capacity to compensate for moderate anemia. Oxygen delivery to tissues depends not only on hemoglobin concentration but also on cardiac output, arterial oxygen saturation, and microcirculatory function. As hemoglobin falls, the heart increases rate and stroke volume, peripheral vasodilation redistributes flow toward vital organs, and tissues extract a larger fraction of the oxygen carried in blood, rising from a normal utilization of about 25 percent to substantially higher levels. Red cells themselves adapt, increasing production of 2,3-bisphosphoglycerate, which shifts the oxygen-hemoglobin dissociation curve to the right and promotes oxygen unloading at the tissue level. These mechanisms explain why many stable patients tolerate hemoglobin levels well below traditional transfusion triggers.

Compensation, however, has limits. Below a critical threshold of oxygen delivery, oxygen consumption becomes supply-dependent, and tissue hypoxia, anaerobic metabolism, lactate accumulation, and organ dysfunction follow. This is why overly restrictive transfusion carries its own dangers, particularly in patients with limited physiological reserve: the elderly, those with coronary or severe lung disease, actively bleeding patients, neonates, and the critically ill with multiple comorbidities. The review emphasizes that the same hemoglobin value can mean very different things in different bodies, depending on cardiovascular reserve, metabolic demand, inflammatory burden, and ongoing blood loss.

Transfusion itself is not a benign intervention. Allogeneic blood exposure carries risks including transfusion-associated circulatory overload, transfusion-related acute lung injury, hemolytic reactions, alloimmunization, iron overload, transfusion-transmitted infection, and transfusion-related immunomodulation. Prolonged storage of red cell units produces the so-called storage lesion, a set of biochemical and structural changes that may impair erythrocyte deformability, reduce nitric oxide availability, and affect oxygen transport and microvascular flow, although its clinical significance remains debated. These hazards, together with global blood shortages and economic constraints, have driven the adoption of Patient Blood Management, an integrated approach endorsed by the World Health Organization, the AABB, the European Society of Anaesthesiology and Intensive Care, and the UK’s National Institute for Health and Care Excellence, which focuses on diagnosing and treating anemia before surgery, minimizing perioperative blood loss, and boosting the patient’s own tolerance of anemia.

Current international guidelines now converge on restrictive thresholds for most hemodynamically stable adults. The AABB recommends considering transfusion below 7 grams per deciliter in stable hospitalized adults, with a slightly higher threshold of about 8 for orthopedic and cardiac surgery patients and those with pre-existing cardiovascular disease. NICE recommends a threshold of 7 with a post-transfusion target of 7 to 9 grams per deciliter, and 8 to 10 for patients with acute coronary syndromes, along with single-unit transfusions followed by clinical reassessment in non-bleeding adults. The Surviving Sepsis Campaign and the European Society of Intensive Care Medicine similarly endorse a 7 gram per deciliter threshold for stable critically ill patients, while the American Society of Anesthesiologists favors individualized perioperative decisions informed by signs of inadequate oxygen delivery such as tachycardia, hypotension, metabolic acidosis, and elevated lactate.

Yet major uncertainties persist in precisely the populations where transfusion decisions matter most. Myocardial tissue extracts oxygen at near-maximal levels even under normal conditions, leaving little compensatory capacity, and trials in acute coronary syndromes have yielded conflicting results: the REALITY trial found restrictive transfusion non-inferior for major cardiovascular events in anemic myocardial infarction patients, while the MINT trial showed only suggestive trends favoring liberal transfusion that did not reach consistent statistical significance. In traumatic brain injury, cerebral tissue is exquisitely vulnerable to hypoxia, but liberal transfusion has not consistently improved neurological outcomes. Evidence also remains thin for patients on extracorporeal membrane oxygenation, those with hematologic malignancies, and frail older adults, who are simultaneously more susceptible to anemia and to transfusion-associated circulatory overload. In massive hemorrhage and trauma, fixed thresholds are largely abandoned in favor of goal-directed, balanced blood component therapy guided by clinical status and viscoelastic testing.

The review argues that the next frontier is precision hemotherapy: replacing the single-number trigger with multivariable algorithms that integrate hemoglobin with serum lactate, central or mixed venous oxygen saturation, near-infrared spectroscopy-derived tissue oxygenation, echocardiographic assessment, and emerging biomarkers of hypoxia, endothelial dysfunction, and iron metabolism such as hepcidin and erythroferrone. Artificial intelligence and machine learning promise to synthesize laboratory data, vital signs, comorbidities, and longitudinal electronic health records to estimate individual transfusion benefit and predict adverse reactions, though the author cautions that prospective validation, algorithmic transparency, and bias mitigation are prerequisites for safe clinical deployment. Digital health tools, continuous physiological monitoring, and wearable biosensors could allow transfusion decisions to evolve dynamically with the patient’s condition. Combined with Patient Blood Management, particularly in resource-constrained settings where blood shortages and weak hemovigilance remain acute challenges, and with greater attention to patient-reported outcomes such as fatigue, functional recovery, and quality of life, these innovations could transform hemotherapy from a threshold-driven reflex into a personalized, physiology-based therapy, conserving a finite biological resource while ensuring that every unit reaches the patient who truly needs it.

Subject of Research: Restrictive versus liberal blood transfusion strategies and the shift toward precision hemotherapy

Article Title: Towards safer and more effective hemotherapy: addressing critical unmet needs in restrictive and liberal blood transfusion strategies

Article References: Obeagu, E. I. (2026). Towards safer and more effective hemotherapy: addressing critical unmet needs in restrictive and liberal blood transfusion strategies. Frontiers in Hematology, 5, Article 1913853. https://doi.org/10.3389/frhem.2026.1913853

Image Credits: AI Generated

DOI: 10.3389/frhem.2026.1913853

Keywords: blood transfusion, restrictive transfusion strategy, liberal transfusion strategy, hemoglobin threshold, patient blood management, TRICC trial, transfusion-related complications, precision hemotherapy, acute coronary syndrome, artificial intelligence, tissue oxygenation, transfusion medicine

The collected studies span an unusually broad surgical landscape, from pediatric cardiac surgery to orthopedic and spine procedures, preoperative optimization, liver transplantation, and complex oncologic surgery. Taken together, they map the full arc of modern PBM: preserving red cell mass before surgery, limiting surgical and coagulopathic bleeding with topical and intravenous treatments, recognizing comorbidities that amplify bleeding risk, and understanding unforeseen postoperative transfusion hazards. Within established PBM programs, hemoglobin thresholds remain useful targets that can reduce transfusion practice at appropriate levels without causing adverse events. But the editorial is emphatic that thresholds alone are insufficient. They represent only a small subset of what works within the three pillars of PBM, and treating them as the whole strategy misses the point of the discipline.

One of the collection’s central reframings is temporal. Transfusion is not a single intraoperative event but the culmination of decisions made throughout the preoperative, intraoperative, and postoperative periods. Nowhere is this clearer than in pediatric cardiac surgery, where a review by Munlemvo examines the mechanisms of coagulopathy in neonates and infants undergoing cardiopulmonary bypass. In these smallest patients, bleeding and thrombosis arise from a delicate imbalance among thrombin generation, platelet activation, fibrinogen availability, antithrombin activity, and fibrinolysis. Because developmental hemostasis produces threshold values that may differ substantially from adult norms, the review argues that pediatric cardiac anesthesiologists need protocols reflecting the biology of developing hemostatic systems rather than simple adoption of adult transfusion triggers.

The same principle of mechanism-driven, patient-specific care applies to adults, where preoperative risk modification can act synergistically with transfusion triggers. A systematic review and meta-analysis by Chen and colleagues found that preoperative erythropoietin reduced both the rate of allogeneic transfusion and the average number of red cell units transfused in adult surgical patients. Critically, the analysis detected no significant differences in mortality, venous thromboembolism, infection, complications, or length of stay between treated and untreated groups. This does not circumvent the need for careful patient selection, thorough anemia evaluation, and vigilance for thrombosis, but it strengthens the case for treating correctable anemia before or during surgery whenever time and clinical context permit. The authors of the editorial note that such evidence also helps erode the lingering stigma surrounding erythropoietin and its perceived risks.

The orthopedic studies in the collection spotlight a problem that is often underappreciated in operating rooms: hidden blood loss. Song and colleagues demonstrated that hidden blood loss accounted for the majority of perioperative bleeding after total hip arthroplasty, and that hypertension, particularly grade 2 or grade 3 disease, was independently associated with greater loss. The implication is striking. Preoperative blood pressure control should be regarded not merely as a cardiovascular safety metric but as an active blood-conservation measure in its own right. Building on this theme, Zhao and colleagues showed that combining intravenous tranexamic acid with intra-articular fluid gelatin substantially reduced total blood loss in elderly patients with femoral neck fractures undergoing total hip arthroplasty, without an observed increase in thromboembolic or wound complications.

Spine surgery adds a complementary lesson about dosing schedules and the timing of antifibrinolytic therapy. In patients undergoing transforaminal lumbar interbody fusion, Ye and colleagues found that intravenous tranexamic acid followed by three days of oral therapy reduced total and hidden blood loss, postoperative drainage, length of stay, and transfusion rates compared with preoperative intravenous therapy alone. Extending the oral regimen to five days added no additional benefit, suggesting a plateau in effect. Together, the orthopedic and spine studies imply that blood management should be tailored not only to the operation being performed but also to the biology and timing of postoperative fibrinolysis, the natural process of clot breakdown that continues for days after tissue injury.

The two major abdominal surgery studies in the collection speak to the genuine complexity of transfusion-outcome associations. Wang and colleagues studied liver transplantation patients and found that intraoperative allogeneic transfusion was associated with acute kidney injury and in-hospital mortality before statistical matching. After propensity matching and multivariable analysis, however, transfusion was no longer an independent risk factor. This illustrates the difficulty of attributing causality to transfusion when confounders such as illness severity, anhepatic time, and the volume of surgical bleeding are in play, and it affirms that allogeneic transfusion remains a necessary measure when clinically appropriate. Li and colleagues reached a different conclusion in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy, where higher intraoperative packed red blood cell volume was associated with poorer overall survival after propensity matching, plausibly reflecting the immunomodulatory effects of transfused blood.

The contrast between these two oncologic and transplant findings is instructive rather than contradictory. Transfusion should neither be reflexively blamed for every adverse outcome nor treated as a neutral exposure when cumulative red cell volume may correlate with modifiable bleeding, inflammatory burden, or surgical complexity. The editorial argues that these studies collectively demand context-aware interpretation of transfusion in high-acuity surgery, where the same unit of blood may be lifesaving in one scenario and a marker of escalating physiologic stress in another. Discerning the difference requires integrating transfusion data with the full clinical picture rather than reading it in isolation.

Across the seven papers, several priorities emerge for the next phase of PBM. First, programs should begin earlier, identifying anemia, uncontrolled hypertension, hypoalbuminemia, anticoagulant exposure, and procedure-specific bleeding risk well before the day of surgery. Second, intraoperative decisions should be guided by mechanism, with antifibrinolytic therapy, topical hemostatic strategies, coagulation testing with or without viscoelastic assays, and transfusion itself stratified according to the patient’s age, diagnosis, operation, and hemostatic phenotype. Third, postoperative surveillance should explicitly include hidden blood loss and anemia recovery. A shared clinical pathway can help multidisciplinary teams synthesize this information into timely, procedure-specific action rather than leaving each decision to individual improvisation.

The Research Topic also exposes significant evidence gaps in transfusion medicine. Many of the included studies are retrospective or single-center, and several evaluate pragmatic interventions in populations with narrow procedural or institutional contexts. Future trials, the editorial argues, should compare bundled, multimodal PBM pathways against usual care, report thrombotic, infectious, renal, functional, and patient-reported outcomes, and clarify definitive transfusion thresholds for children, older adults, patients with cardiovascular disease, patients with liver failure, and those undergoing major cancer surgery. Real-world implementation will be equally important, because a protocol that performs well under ideal clinical conditions may fail if screening, testing, blood availability, or multidisciplinary communication are unreliable. The ultimate message is one of calibrated precision rather than restriction. Optimal perioperative transfusion management is less about withholding blood and more about choosing the right intervention at the right moment. Blood products remain lifesaving when hemorrhage threatens oxygen delivery and organ perfusion, yet avoidable transfusion is itself a modifiable exposure. By connecting preoperative optimization, mechanism-based hemostasis, disciplined transfusion practice, and postoperative recovery metrics, perioperative teams can move closer to genuinely patient-centered blood management, achieving safer surgery through preservation of the patient’s own physiologic reserve.

Subject of Research: Perioperative blood transfusion management and patient blood management strategies across surgical settings

Article Title: Editorial: Perioperative blood transfusion management in the perioperative setting

Article References: Henderson, R. (2026). Editorial: Perioperative blood transfusion management in the perioperative setting. Frontiers in Anesthesiology, 5, Article 1971889. https://doi.org/10.3389/fanes.2026.1971889

Image Credits: AI Generated

DOI: 10.3389/fanes.2026.1971889

Keywords: patient blood management, blood transfusion, perioperative medicine, tranexamic acid, hidden blood loss, anemia, coagulopathy, orthopedic surgery, liver transplantation, erythropoietin, hemostasis, anesthesiology

The research, published as an open-access article in Annals of Hematology by a team at Birjand University of Medical Sciences, focused on 74 patients with transfusion-dependent beta-thalassemia. This inherited blood disorder prevents the body from producing healthy hemoglobin, the protein that carries oxygen in red blood cells, and patients depend on regular transfusions to survive. The team divided participants into two groups: seven patients who had developed alloantibodies against donor red cell antigens, and 67 transfused patients who had not, serving as disease controls. The researchers then used a targeted molecular technique called PCR-SSP, or polymerase chain reaction with sequence-specific primers, to detect three specific HLA-DRB1 variants: HLA-DRB107:01, HLA-DRB110, and HLA-DRB1*12.

The results were dramatic, if preliminary. HLA-DRB110 was detected in three of the seven alloimmunized patients but in only one of the 67 non-alloimmunized controls, yielding a Fisher’s exact test p-value of 0.002 and an odds ratio of 49.50 with a 95 percent confidence interval stretching from 4.64 to 528.21. Even more striking, HLA-DRB112 was found in two of the seven alloimmunized patients and in none of the controls, producing a p-value of 0.008. Because no controls carried this variant, the researchers could not calculate a stable odds ratio for the association, a statistical phenomenon known as a zero cell. No significant association emerged for HLA-DRB1*07:01.

To understand why these findings matter, it helps to grasp the immunology at play. HLA molecules are the human version of the major histocompatibility complex, a family of cell-surface proteins that present peptide fragments to T lymphocytes and thereby orchestrate adaptive immune responses. HLA class II molecules, including those encoded by the DRB1 gene, are expressed on professional antigen-presenting cells such as dendritic cells, macrophages, and B cells. When a transfused red cell carries an antigen that the recipient lacks, that antigen is taken up, processed, and presented by the recipient’s HLA class II machinery to helper T cells. If the T cells recognize the presented peptide as foreign, they can drive B cells to mature into antibody-producing plasma cells, generating alloantibodies that circulate for years and can destroy transfused cells carrying the offending antigen.

The specific antibodies found in this cohort tell their own story. Anti-E, directed against the E antigen of the Rh blood group system, and anti-K, directed against the K antigen of the Kell system, were the most frequent specificities detected. Both are clinically significant: anti-E is among the most common immune antibodies encountered in transfusion practice, while anti-K is notorious for causing hemolytic transfusion reactions and hemolytic disease of the fetus and newborn. Most of the alloimmunized patients in the study were what transfusion specialists call hyper-responders, individuals who mounted antibody responses to multiple antigens rather than just one, a pattern that makes compatible blood procurement exponentially more difficult.

The frequency of alloimmunization in this cohort, 9.5 percent, sits within the range reported for thalassemia populations worldwide, though estimates vary widely between studies, from a few percent to more than 30 percent depending on the population, transfusion protocols, and antigen-matching practices. What sets the new study apart is its attempt to link this variability to immunogenetics. The hypothesis that HLA class II polymorphisms shape alloimmunization risk is not new; immune response genes have long been suspected of determining why some patients respond vigorously to foreign red cell antigens while others tolerate them silently. But direct evidence in thalassemia has been sparse, and the Iranian province of South Khorasan, with its distinctive genetic heritage, offered an opportunity to test the idea in a specific population.

The authors themselves are careful to frame their findings as exploratory and hypothesis-generating rather than definitive. With only seven alloimmunized patients, the statistical power is limited, and the confidence interval around the odds ratio for HLA-DRB110 is extraordinarily wide, reflecting the sparse data. Small case-control studies of rare outcomes are prone to both false positives and inflated effect sizes, a well-documented phenomenon in genetic association research. The zero cell problem for HLA-DRB112 compounds this uncertainty, since standard statistical methods cannot produce a stable estimate when one group has no cases of the exposure. The researchers explicitly call for validation in larger, geographically diverse cohorts before any clinical conclusions can be drawn.

Nevertheless, the biological plausibility of the association is compelling. Different HLA-DRB1 alleles present different peptide repertoires with varying efficiency, and it is conceivable that certain variants are particularly adept at presenting red cell-derived peptides to helper T cells, thereby lowering the threshold for alloantibody formation. If confirmed, such a mechanism would explain why hyper-responder phenotypes cluster in some patients and why alloimmunization rates differ across ethnic groups with distinct HLA distributions. It would also open the door to a form of personalized transfusion medicine in which a patient’s HLA genotype, determined once at diagnosis, informs the intensity of extended antigen matching for the blood they receive throughout life.

The practical implications for thalassemia care are significant. Patients who develop alloantibodies face longer waits for compatible units, increased risk of delayed hemolytic transfusion reactions, and higher transfusion-related morbidity overall. In regions where the thalassemia gene is common and blood supplies are strained, the ability to identify genetically susceptible patients before they ever mount an antibody response could transform transfusion support from a reactive process into a preventive one. Extended phenotyping or genotyping of both donors and recipients, guided by immunogenetic risk profiles, could reduce the incidence of alloimmunization and ease the chronic shortage of compatible blood for the most vulnerable patients.

The study, conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Birjand University of Medical Sciences, was supported financially and administratively by the same institution. The research team, led by corresponding author Fatemeh Mezginejad of the Department of Hematology at the School of Allied Medicine, included Mohammad Javad Yousefi and Mobina Nakhaei Shamahmood from the Student Research Committee and Mansoor Soltani from the Department of Critical Care Nursing. As the field awaits larger validation studies, the work stands as a provocative early signal that the immune genes governing transfusion compatibility may be far more personal than the blood on the shelf suggests, and that the future of safe transfusion in thalassemia may lie as much in the genome as in the donor database.

Subject of Research: HLA-DRB1 genetic variants and red cell alloimmunization risk in transfusion-dependent thalassemia

Article Title: Association of HLA-DRB1*12 with red cell alloimmunization in transfusion-dependent thalassemia

Article References: yousefi, M. J., Nakhaei Shamahmood, M., Soltani, M., & Mezginejad, F. (2026). Association of HLA-DRB1*12 with red cell alloimmunization in transfusion-dependent thalassemia. Annals of Hematology. https://doi.org/10.1007/s00277-026-07321-5

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07321-5

Keywords: HLA-DRB1, alloimmunization, thalassemia, blood transfusion, alloantibodies, immunogenetics, transfusion medicine, red blood cells, anti-E, anti-K, PCR-SSP, Iran

The central premise of the review is that improved survival has created a new clinical population with new needs. Advances in transfusion regimens, iron chelation drugs that bind excess iron and allow the body to excrete it, and coordinated multidisciplinary care have dramatically extended life expectancy for people with transfusion-dependent beta-thalassemia. Many women now survive well into their reproductive years and beyond, and their reproductive potential has improved in parallel. Pregnancy, once a rare event in this population, has become increasingly feasible, although the authors are emphatic that it remains a high-risk condition that demands specialized management rather than routine obstetric care. The review is designed as a practical roadmap for hematologists, obstetricians, endocrinologists, cardiologists, and primary care providers who may encounter these patients only occasionally but must coordinate their care intensively.

The foundation of a safe pregnancy, according to the review, is laid long before conception. The authors call for comprehensive preconception evaluation by a multidisciplinary team, covering cardiac function, iron overload, endocrine disorders, liver disease, kidney function, fertility, and genetic risk. Each of these domains reflects a distinct vulnerability created by the disease and its treatment. Chronic anemia forces the heart to work harder, and accumulated iron can stiffen and weaken the cardiac muscle directly. The endocrine axis is particularly fragile: iron deposition in the pituitary gland, gonads, thyroid, and pancreas can impair hormone production, and many women with the condition require hormonal support to ovulate at all. Liver disease and reduced kidney reserve add further layers of risk. Genetic counseling is also essential, because beta-thalassemia is inherited in an autosomal recessive pattern, meaning that the carrier status of the partner determines whether each pregnancy carries a risk of affected offspring.

Cardiac assessment emerges as perhaps the most consequential element of the preconception workup. Myocardial iron overload, detectable with cardiovascular magnetic resonance imaging, is the leading cause of mortality in people with transfusion-dependent thalassemia, and pregnancy places substantial additional hemodynamic demands on the heart, with blood volume increasing by roughly forty to fifty percent and cardiac output rising accordingly. The review emphasizes that women with significant myocardial iron require particularly careful planning, and that early identification and treatment of iron overload and cardiac disease remain essential for optimizing outcomes. In practice, this means that the cardiac evaluation is not a one-time gatekeeping exercise but a recurring process that continues throughout pregnancy, with periodic cardiac assessment recommended for all patients as gestation progresses.

Once pregnancy is established, the review recommends maintaining pre-transfusion hemoglobin levels at ten grams per deciliter or higher, a more aggressive target than the thresholds typically used in non-pregnant patients with the condition. The rationale is physiological: the fetus depends entirely on maternal oxygen delivery, and the expanded plasma volume of pregnancy dilutes the maternal red cell mass. More frequent transfusions are usually required to hit the target, which in turn accelerates iron accumulation, creating a delicate balancing act between protecting fetal oxygenation and limiting maternal iron burden. The authors also recommend regular fetal growth surveillance, because placental insufficiency and intrauterine growth restriction are recognized complications in this population, alongside screening for gestational diabetes, which is more common in women with thalassemia-related endocrine dysfunction and iron overload, and individualized thromboprophylaxis for patients judged to be at high risk of venous thromboembolism.

Iron chelation policy during pregnancy is one of the most nuanced areas the review addresses. The standard oral and oral-agent chelators, deferiprone and deferasirox, are not established as safe in pregnancy, and the general recommendation is that chelation therapy should be discontinued once conception is confirmed. However, the authors note an important exception for women with severe cardiac or hepatic iron overload. For these patients, deferoxamine, an older chelator administered by continuous subcutaneous or intravenous infusion that does not cross the placenta appreciably, may be considered from the second trimester onward. In women with significant myocardial iron, deferoxamine has been used from approximately twenty weeks of gestation, or earlier when clinically indicated. This individualized approach reflects a risk-benefit calculation: the danger of untreated cardiac iron, which can precipitate heart failure during the hemodynamic stress of late pregnancy and delivery, can outweigh the theoretical fetal risks of exposure in selected cases.

The review also maps out the peripartum and postpartum terrain, which carries its own distinct hazards. Women with thalassemia-related endocrine dysfunction may face impaired uterine contractility and increased bleeding risk, while splenectomy, performed in some patients to reduce transfusion requirements, is associated with a higher risk of thromboembolic events, making individualized thromboprophylaxis particularly important in that subgroup. Cesarean delivery may be indicated for obstetric reasons, but it is not mandated by the disease itself. After delivery, the resumption of chelation must be coordinated with infant feeding choices, since chelators are excreted in breast milk, and the maternal transfusion schedule and iron monitoring must be re-established promptly. The authors stress that adherence to evidence-based recommendations across this entire continuum substantially reduces maternal and fetal complications.

What makes the review notable is its synthesis of forty discrete recommendations into a coherent care pathway, effectively converting scattered international guidance into a single clinical reference. The authors systematically reviewed publications including clinical practice guidelines, systematic reviews, meta-analyses, and original studies to identify evidence across preconception counseling, maternal assessment, antenatal care, transfusion strategy, chelation, fetal surveillance, delivery, and postpartum management. This breadth matters because care for these women is inherently fragmented: a hematologist manages transfusions and iron, an endocrinologist manages hormonal induction of ovulation and diabetes risk, a cardiologist tracks cardiac iron and function, and an obstetrician manages fetal surveillance and delivery. The review’s contribution is to bind those threads together and to make explicit where evidence is strong and where recommendations rest on expert consensus rather than randomized trials, a distinction that is important in a field where pregnancy is too rare and too risky for large controlled studies.

The implications extend beyond individual clinics. As survival in transfusion-dependent beta-thalassemia continues to improve worldwide, particularly in the Mediterranean, Middle East, and South and Southeast Asia where the disease is most prevalent, the number of women reaching reproductive age and seeking pregnancy will only grow. Health systems that have historically focused on pediatric transfusion care will need to build adult and reproductive services, including fertility preservation and assisted reproduction, since spontaneous conception is often impossible in women with iron-induced hypothalamic-pituitary damage. The review’s emphasis on early identification and treatment of iron overload, cardiac disease, and endocrine dysfunction is, in effect, an argument for lifelong preventive care beginning in childhood, so that women who wish to become pregnant arrive at that decision with organs as protected as possible.

For patients and families, the message is one of cautious, conditional optimism. Pregnancy in women with transfusion-dependent beta-thalassemia is still classified as high risk, and the review does not minimize the vigilance it demands: pre-transfusion hemoglobin held at or above ten grams per deciliter, periodic cardiac evaluation, gestational diabetes screening, fetal growth monitoring, and carefully individualized decisions about chelation. But the central finding is unambiguous. With comprehensive preconception planning, multidisciplinary management, regular monitoring, and adherence to the evidence-based recommendations now assembled in one place, favorable maternal and fetal outcomes are achievable. What was once dismissed as medically impossible has become a realistic goal, provided that the pregnancy is planned, monitored, and supported by a team that understands both the disease and the profound physiological transformations of gestation.

Subject of Research: Management of pregnancy in women with transfusion-dependent beta-thalassemia

Article Title: Management of pregnancy in women with transfusion-dependent β-thalassemia: An evidence-based narrative review with clinical recommendations

Article References: Miri-Aliabad, G., & Dahmardeh, T. (2026). Management of pregnancy in women with transfusion-dependent β-thalassemia: An evidence-based narrative review with clinical recommendations. Annals of Hematology. https://doi.org/10.1007/s00277-026-07309-1

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07309-1

Keywords: beta-thalassemia, transfusion-dependent thalassemia, pregnancy, blood transfusion, iron overload, iron chelation, deferoxamine, preconception care, fertility, gestational diabetes, genetic counseling, maternal-fetal outcomes

Toxoplasma gondii is one of the most successful parasites on Earth. It reproduces sexually only in cats, but its infectious oocysts shed in cat feces can contaminate soil, water, and food, while tissue cysts harbored in undercooked meat provide another common route of infection. In healthy people, the parasite usually causes mild or unnoticed symptoms before settling into a lifelong dormant state, encysted within muscles and the brain. The immune system keeps it in check, but it never eliminates it entirely. That delicate equilibrium is what makes the parasite so dangerous for people whose defenses are compromised. In immunocompromised patients, dormant cysts can reactivate, and newly acquired infections can escalate into life-threatening encephalitis, pneumonia, or systemic disease.

Beta-thalassemia major sits at an unusual intersection of vulnerability. Patients cannot produce adequate functional hemoglobin because of genetic defects in the beta-globin chain, and without regular transfusions of donor red blood cells every few weeks, they would not survive childhood. Decades of transfusion therapy, however, bring their own consequences: iron overload that itself impairs immune function, splenectomy in many patients that removes a key immune filter for blood-borne pathogens, and chronic inflammatory states that dysregulate cellular immunity, the very arm of the immune system, driven by T cells, that normally keeps Toxoplasma dormant. Layered on top of this is the theoretical possibility that the parasite could be transmitted directly through transfused blood, since Toxoplasma tachyzoites, the rapidly dividing form, can circulate in donor blood, and the parasite has been shown to survive in stored blood products under laboratory conditions.

To quantify the association, the research team followed the PRISMA reporting guidelines and searched PubMed, Scopus, and Web of Science from database inception through July 24, 2025. From an initial pool of 45 records, fourteen studies met the inclusion criteria: eleven case-control studies and three cross-sectional studies that reported IgG or IgM seropositivity for Toxoplasma gondii in beta-thalassemia major patients. Two reviewers independently extracted the data, a standard safeguard against extraction errors. The investigators pooled prevalence estimates using random-effects models, which do not assume that all studies estimate the same underlying true value and therefore better accommodate clinical and methodological diversity across settings. Heterogeneity, the statistical signature of between-study variation, was assessed with the I² statistic and Cochran’s Q test, and the methodological quality of each study was appraised using the design-specific Joanna Briggs Institute checklists.

The headline numbers are striking. The pooled prevalence of Toxoplasma infection among thalassemia patients was 21.5 percent, with a 95 percent confidence interval of 16.2 to 27.9 percent. Breaking the results down by antibody class, the seroprevalence of IgG, which indicates past exposure and chronic, latent infection, reached 30.0 percent, while IgM, a marker of recent or active infection, stood at 4.8 percent. When the researchers compared patients directly with healthy controls, the overall pooled risk ratio was 2.30, meaning thalassemia patients had more than twice the odds of testing positive. The subgroup analysis sharpened the picture: the risk ratio for IgG seropositivity was 2.05, while for IgM it climbed to 3.46, suggesting that recent infection may be disproportionately elevated in this population, a pattern that would be consistent with ongoing exposure rather than merely accumulated lifetime risk.

Rigorous meta-analyses live or die by their robustness checks, and this one ran the full gauntlet. Eight of the fourteen studies were rated high quality, one moderate, and five low, and critically, the pooled prevalence was not inflated by the lower-quality studies, a common pitfall in observational syntheses. Leave-one-out sensitivity analysis, in which each study is removed in turn to test whether any single dataset drives the result, confirmed the stability of the pooled estimates. Meta-regression found no significant effect of publication year or sample size on the observed heterogeneity, although subgroup analysis did identify study design as a potential source of that variation, with the very high I² values of 94.0 percent overall reflecting substantial statistical diversity among the included populations, assays, and diagnostic methods.

The analysis was less reassuring on the question of publication bias. Funnel plot asymmetry was statistically significant, with Begg’s test yielding a p-value of 0.0007 and Egger’s test a p-value below 0.0001, patterns that often arise when small studies with dramatic findings are published more readily than small null studies. Trim-and-fill analysis, a statistical imputation technique that estimates how many studies might be missing from the funnel plot, suggested that unpublished studies could be absent from the risk-ratio outcomes, meaning the true association, while likely real, could be somewhat smaller than the headline estimate of 2.30.

The authors are careful, and rightly so, about what the data cannot show. Seroprevalence studies detect antibodies, not the parasite itself, and they cannot distinguish between infection acquired through contaminated food or water, reactivation of latent infection under immune pressure, and transmission via transfused blood. All three mechanisms are biologically plausible in thalassemia patients. Iron overload is known to impair macrophage and T-cell function, potentially allowing latent cysts to reactivate. Splenectomized patients clear intracellular pathogens less effectively. And transfusion transmission, while never proven in this analysis, remains a theoretical concern given that seronegative donors are not routinely screened for Toxoplasma in most blood banks, unlike for HIV, hepatitis B, hepatitis C, and syphilis. The observational design of every included study means causality cannot be assigned to any of these pathways.

Even with those caveats, the practical implications are difficult to ignore. Millions of people worldwide live with thalassemia, concentrated in the Mediterranean, Middle East, and South and Southeast Asia, regions that overlap substantially with areas of high Toxoplasma endemicity. The finding that roughly one in five thalassemia patients in the pooled studies showed serological evidence of infection, and that recent infection markers were more than three times as common as in controls, gives clinicians a concrete reason to consider toxoplasmosis in the differential diagnosis of febrile or neurologically symptomatic thalassemia patients. It also strengthens the case, as the authors argue, for evaluating preventive strategies, from donor screening studies to patient education about food hygiene, in this vulnerable population. Whether routine Toxoplasma screening of blood donations is justified will require direct evidence of transfusion-transmitted cases, cost-effectiveness modeling, and an assessment of how frequently the parasite survives standard blood storage, questions that this meta-analysis cannot answer but that its results now make considerably harder to defer.

What the study ultimately delivers is a well-characterized signal demanding mechanistic follow-up. The statistical work is thorough, the sensitivity analyses are reassuring, and the authors’ transparency about publication bias and the limits of observational evidence reflects the kind of epistemic discipline that meta-analyses of this kind require. For the thalassemia community, the message is not alarm but attention: a parasite that most people shrug off may deserve a place on the clinical radar of transfusion-dependent patients, and the blood supply that keeps them alive may deserve a closer look for one of the world’s most widespread and quietly persistent pathogens.

Subject of Research: Toxoplasma gondii seroprevalence and infection risk in patients with beta-thalassemia major

Article Title: Elevated seroprevalence and risk of Toxoplasma gondii infection in patients with beta-thalassemia major: a systematic review and meta-analysis

Article References: Lesani, S., Hayati, F., & Boozhmehrani, M. J. (2026). Elevated seroprevalence and risk of Toxoplasma gondii infection in patients with beta-thalassemia major: a systematic review and meta-analysis. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14558-y

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14558-y

Keywords: Toxoplasma gondii, beta-thalassemia major, seroprevalence, meta-analysis, blood transfusion, transfusion-transmitted infections, immunocompromised patients, IgG antibodies, IgM antibodies, publication bias, systematic review, preventive strategies

The stakes of this comparison are straightforward. HIV is transmissible through transfused blood with exceptionally high efficiency, far higher than through most other routes of exposure, because a transfusion delivers infected blood directly into a recipient’s circulation. A single unscreened or inadequately screened donation can therefore establish infection in a recipient with near certainty. This is why wealthy countries long ago adopted multi-layered screening that combines antibody and antigen detection with molecular testing of pooled samples. In many low- and middle-income countries, however, the cost and technical demands of molecular platforms have kept rapid serological tests at the center of blood safety programs, and Mozambique has been no exception.

The routine algorithm evaluated in the study pairs two rapid tests: the Determine HIV 1/2 assay, which detects antibodies to HIV-1 and HIV-2, followed by the Uni-Gold HIV test as a confirmatory or tie-breaking step. This combination is the standard approach for screening blood donor candidates in Mozambique. The researchers also examined two newer rapid tests, the Determine HIV Early Detect assay and the Meriscreen HIV1-2 Western Blot test, both of which are designed to shorten the window period by adding detection of the p24 viral antigen to antibody detection. As a laboratory-based comparator, the team used the Merilisa HIV Gen 4 enzyme-linked immunosorbent assay combined with Uni-Gold, and as a molecular reference they used the cobas MPX test, a nucleic acid amplification platform that detects viral RNA and can identify infection during the earliest phase before antibodies appear.

When the rapid algorithms were benchmarked against the Merilisa HIV Gen 4 enzyme immunoassay plus Uni-Gold, their performance looked reasonably strong on the surface. The routine Determine HIV 1/2 plus Uni-Gold combination achieved a sensitivity of 85.5 percent and a specificity of 99.6 percent. The Determine HIV Early Detect test reached 88.7 percent sensitivity with 99.5 percent specificity, while the Meriscreen HIV1-2 Western Blot assay performed best among the rapid options at 90.0 percent sensitivity and 99.6 percent specificity. In other words, the newer rapid assays caught a somewhat larger share of infections than the routine algorithm while maintaining the very low false-positive rates that blood banks require to avoid discarding safe donations.

The picture changed dramatically, however, when the researchers measured all of the serological approaches against the cobas MPX molecular test. Sensitivity fell steeply across the board. The routine Determine HIV 1/2 plus Uni-Gold algorithm detected only 64.0 percent of the infections identified by the molecular assay, with 99.1 percent specificity. Determine HIV Early Detect rose to 68.6 percent sensitivity at 99.1 percent specificity, and Meriscreen HIV1-2 Western Blot reached 70.8 percent sensitivity at 99.0 percent specificity. Even the laboratory-based Merilisa HIV Gen 4 plus Uni-Gold combination, which one might expect to approach molecular performance, detected just 66.0 percent of molecularly positive samples at 99.4 percent specificity. These figures mean that a substantial fraction of donations carrying HIV, roughly a third by these comparisons, would pass through serological screening undetected.

The clinical translation of those percentages is sobering. The researchers calculated that the probability of an undetected positive result ranged from 5.6 to 6.7 per 1,000 blood donors across the rapid tests and the Merilisa HIV Gen 4 assay. In a country where tens of thousands of donations are collected annually, that residual risk translates into a meaningful number of potentially infectious units entering the blood supply each year. The source of the discrepancy lies in the biology of HIV infection. Serological tests depend on the host immune response, and there is an unavoidable window period between infection and the appearance of detectable antibodies or antigen. During that window, viral RNA circulates at high levels and the donor is highly infectious, yet antibody-based assays return negative results. Molecular tests close much of that gap by directly detecting viral genetic material.

The study’s design deserves attention because it goes beyond a simple head-to-head comparison of commercial kits. By establishing a molecular reference standard and evaluating multiple testing strategies against it, the team was able to quantify not only relative sensitivity and specificity but also the practical consequence of relying on serology alone: an estimated residual transmission risk per thousand donors. This kind of risk estimate is the currency in which blood safety policy is debated, because it allows program managers to weigh the cost of adding nucleic acid testing against the expected number of transfusion-transmitted infections prevented. The authors argue that their results point directly to the need for molecular HIV testing in blood banks in developing countries as a way to improve transfusion safety and contribute to controlling HIV as a public health problem.

That recommendation is not without challenges. Nucleic acid amplification testing requires sophisticated laboratory infrastructure, trained personnel, cold-chain logistics, reliable electricity, and quality management systems, and it is considerably more expensive per sample than rapid testing. Many programs address the cost by testing donations in minipools, in which multiple samples are combined and screened together, with individual follow-up testing only when a pool is reactive. The cobas MPX platform used as the molecular comparator in this study is precisely the kind of multiplex nucleic acid test that supports such pooled screening strategies, and it can simultaneously detect HIV, hepatitis B virus, and hepatitis C virus, extending the safety benefit beyond HIV alone. Whether such platforms can be sustainably deployed in Mozambique and similar settings will depend on financing, laboratory capacity, and political commitment to blood safety as an integral component of HIV control.

The findings also carry implications for how rapid tests are selected and deployed in the interim. The newer assays that incorporate antigen detection, Determine HIV Early Detect and Meriscreen HIV1-2 Western Blot, outperformed the routine antibody-only algorithm in both comparisons, suggesting that upgrading the rapid testing algorithm could deliver incremental gains while molecular capacity is being built. The differences were modest, however, and the study makes clear that no serological strategy, whether rapid or laboratory-based, can match the sensitivity of direct viral detection during early infection. Specificity remained uniformly high across all tests, above 99 percent in every comparison, which means the problem is not false alarms but silent misses, the most dangerous failure mode in a transfusion setting.

Ultimately, the study provides the kind of local, context-specific evidence that global guidelines often lack. International recommendations on blood screening assume a level of diagnostic capacity that many national programs cannot yet deliver, and country-level performance data are essential for making the economic and public health case for investment. By quantifying the residual risk of HIV transmission through transfusion under the current Mozambican screening algorithm, Mabunda and colleagues have converted an abstract concern into a concrete number that policymakers can act on. As the authors conclude, introducing molecular testing into blood banks in developing countries would improve transfusion safety and strengthen the broader effort to bring HIV under control, a goal that depends on closing every remaining route of transmission, including the one that runs through the blood supply.

Subject of Research: Analytical performance of HIV serological screening tests for blood donor candidates in Mozambique

Article Title: High transmission risk of Human Immunodeficiency Virus in blood transfusions: A critical evaluation of blood bank serological tests in Mozambique

Article References: Mabunda, N., Matola, O., Sambo, J., Chelene, I., Munguambe, A., Abílio, N., Vubil, A., Loquiha, O., & Jani, I. (2026). High transmission risk of Human Immunodeficiency Virus in blood transfusions: A critical evaluation of blood bank serological tests in Mozambique. PLOS Global Public Health, 6(9), e0007398. https://doi.org/10.1371/journal.pgph.0007398

Image Credits: AI Generated

DOI: 10.1371/journal.pgph.0007398

Keywords: HIV, blood transfusion, blood banks, serological tests, rapid diagnostic tests, ELISA, molecular testing, Mozambique, transfusion safety, sub-Saharan Africa, screening, public health

Cancer-related anemia, often abbreviated CRA, arises from a tangle of mechanisms: the tumor itself can suppress red blood cell production through inflammatory cytokines, chemotherapy and radiotherapy damage the bone marrow, nutritional iron deficiency can develop, and bleeding or kidney dysfunction can compound the deficit. The result is a reduced hemoglobin concentration, which starves tissues of oxygen and manifests clinically as fatigue, breathlessness, dizziness, and diminished quality of life. In late-stage disease, where patients are often receiving their third or subsequent lines of treatment, the cumulative toxicity of repeated regimens makes the problem especially acute.

The Beijing study quantified the severity of anemia using standard hemoglobin thresholds. Among the 1,006 anemic patients, the average hemoglobin level was 96.85 grams per liter, with a standard deviation of 14.32. Mild anemia accounted for just over half of cases at 51.3 percent, moderate anemia for 35.8 percent, severe anemia for 10.2 percent, and extremely severe anemia for 2.7 percent. In other words, roughly one in eight anemic patients had fallen into a range serious enough to threaten daily functioning and potentially require urgent intervention.

Red blood cell morphology added another layer of diagnostic insight. Normocytic anemia — red cells of normal size — predominated at 75.3 percent of cases, a pattern consistent with the anemia of chronic disease and marrow suppression rather than classic iron deficiency. Macrocytic anemia, in which red cells are abnormally large, followed at 20.7 percent, a finding that can reflect chemotherapy effects on DNA synthesis, folate or vitamin B12 disturbances, or certain targeted therapies. Microcytic anemia, typically associated with absolute iron deficiency, was the least common at just 4.0 percent, suggesting that straightforward iron replacement alone would address only a small fraction of the problem in this population.

The distribution of severity varied meaningfully by tumor type. Advanced lung cancer and gastrointestinal tumors had the highest proportions of mild anemia, at 56.2 percent and 55.4 percent respectively, meaning most of their anemic patients remained in the least severe category. Gynecologic tumors told a different story: 18.2 percent of anemic patients with these cancers had severe anemia, a rate significantly higher than the 6.3 percent seen in advanced lung cancer and the 6.0 percent in breast cancer. The authors suggest this may reflect the biology and treatment of gynecologic malignancies, including the potential for tumor-related and treatment-related blood loss, though the retrospective design cannot pin down the exact mechanisms.

Perhaps the most sobering finding concerns treatment. Despite the availability of established therapies for cancer-related anemia — iron supplementation, erythropoiesis-stimulating agents, and red blood cell transfusion — only 22.4 percent of the 1,006 anemic patients received any anti-anemia therapy. The treatment gap tracked severity closely: just 10.1 percent of patients with mild anemia were treated, compared with 59.2 percent of those with severe anemia and 96.3 percent of those with very severe anemia. The pattern suggests that clinicians often wait until anemia becomes debilitating before intervening, a reactive approach that the study’s authors argue should give way to earlier, standardized management.

To identify who is most at risk of severe anemia, the researchers performed multivariate logistic regression, a statistical technique that isolates the independent effect of each factor while controlling for the others. The results were revealing. A Karnofsky Performance Status score of 60 or higher — a measure of a patient’s functional ability, where higher scores indicate better day-to-day functioning — was associated with an approximately 62 percent reduction in the odds of severe anemia, with an odds ratio of 0.38. This suggests that a patient’s overall physical condition, and the biological reserve it represents, plays a protective role against the steepest hemoglobin declines.

Tumor type emerged as another independent determinant. Compared with lung cancer, gynecologic tumors carried roughly 3.3 times the risk of severe anemia, with an odds ratio of 3.33, while gastrointestinal tumors carried 1.83 times the risk. A prior history of blood transfusion was also linked to a 76 percent increase in the risk of severe anemia, with an odds ratio of 1.76 — a finding that likely marks patients whose anemia has already proven refractory or recurrent, rather than transfusion itself causing the problem. Notably, age, gender, history of prior tumors, the specific third-line regimen, stage IV disease at initial diagnosis, liver metastasis, and lung metastasis showed no independent association with severe anemia, indicating that these commonly monitored variables are less predictive than performance status and tumor origin.

The study joins a lineage of large surveys, including the European Cancer Anaemia Survey, that have documented the high prevalence and undertreatment of anemia in oncology. What distinguishes the new work is its focus on a heavily pretreated population — patients on third-line or later therapy — a group that is often underrepresented in clinical trials yet increasingly common as cancer survival extends and treatment sequences lengthen. With an incidence of 65.1 percent in this setting, anemia is not a marginal side effect but a central feature of advanced disease management, with direct consequences for treatment tolerance, dosing intensity, and quality of life.

The authors conclude that greater attention and standardized management of anemia should be implemented among cancer patients, and the data point to concrete priorities: routine hemoglobin monitoring and earlier intervention for patients with gynecologic and gastrointestinal tumors, proactive anemia assessment for those with poor performance status, and a lower threshold for treatment before hemoglobin levels fall into the severe range. As cancer care continues to extend lives through successive lines of therapy, the study serves as a reminder that the blood counts of these patients deserve the same systematic attention as their tumors.

Subject of Research: Cancer-related anemia in advanced cancer patients receiving third-line or higher anti-cancer treatment

Article Title: A survey of the current status of cancer-related anemia in 1006 advanced cancer patients undergoing third-line or higher anti-cancer treatment: a multicenter retrospective study in nine tertiary hospitals in Beijing area

Article References: Xu, J., Zhang, Q., Kang, N., Yan, D., Feng, Y., Yin, Y., Liu, J., Jiang, J., Yuan, J., Liu, Z., Han, X., Li, X., & Hou, L. (2026). A survey of the current status of cancer-related anemia in 1006 advanced cancer patients undergoing third-line or higher anti-cancer treatment: a multicenter retrospective study in nine tertiary hospitals in Beijing area. BMC Cancer. https://doi.org/10.1186/s12885-026-17100-0

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17100-0

Keywords: cancer-related anemia, advanced cancer, hemoglobin, chemotherapy, gynecologic tumors, gastrointestinal tumors, lung cancer, performance status, blood transfusion, retrospective study, anemia treatment, oncology